243 related articles for article (PubMed ID: 36043552)
21. Analysis of the EGFR Amplification and CDKN2A Deletion Regulated Transcriptomic Signatures Reveals the Prognostic Significance of
Wang H; Wang X; Xu L; Zhang J; Cao H
Front Oncol; 2021; 11():551160. PubMed ID: 33959491
[No Abstract] [Full Text] [Related]
22. Selenoprotein GPX1 is a prognostic and chemotherapy-related biomarker for brain lower grade glioma.
Chen X; Fu G; Li L; Zhao Q; Ke Z; Zhang R
J Trace Elem Med Biol; 2022 Dec; 74():127082. PubMed ID: 36155420
[TBL] [Abstract][Full Text] [Related]
23. CHI3L2 Is a Novel Prognostic Biomarker and Correlated With Immune Infiltrates in Gliomas.
Liu L; Yang Y; Duan H; He J; Sun L; Hu W; Zeng J
Front Oncol; 2021; 11():611038. PubMed ID: 33937022
[TBL] [Abstract][Full Text] [Related]
24. Expression profile analysis of antisense long non-coding RNA identifies WDFY3-AS2 as a prognostic biomarker in diffuse glioma.
Wu F; Zhao Z; Chai R; Liu Y; Wang K; Wang Z; Li G; Huang R; Jiang H; Zhang K
Cancer Cell Int; 2018; 18():107. PubMed ID: 30069164
[TBL] [Abstract][Full Text] [Related]
25. PTPRN Serves as a Prognostic Biomarker and Correlated with Immune Infiltrates in Low Grade Glioma.
Li P; Chen F; Yao C; Zhu K; Zhang B; Zheng Z
Brain Sci; 2022 Jun; 12(6):. PubMed ID: 35741647
[TBL] [Abstract][Full Text] [Related]
26. Elevated TYROBP expression predicts poor prognosis and high tumor immune infiltration in patients with low-grade glioma.
Lu J; Peng Y; Huang R; Feng Z; Fan Y; Wang H; Zeng Z; Ji Y; Wang Y; Wang Z
BMC Cancer; 2021 Jun; 21(1):723. PubMed ID: 34162355
[TBL] [Abstract][Full Text] [Related]
27. A pan-cancer perspective analysis reveals the opposite prognostic significance of CD133 in lower grade glioma and papillary renal cell carcinoma.
Wang H; Wang X; Xu L; Zhang J; Cao H
Sci Prog; 2021; 104(2):368504211010938. PubMed ID: 33878963
[TBL] [Abstract][Full Text] [Related]
28. Distinct phenotypic differences associated with differential amplification of receptor tyrosine kinase genes at 4q12 in glioblastoma.
Burford A; Little SE; Jury A; Popov S; Laxton R; Doey L; Al-Sarraj S; Jürgensmeier JM; Jones C
PLoS One; 2013; 8(8):e71777. PubMed ID: 23990986
[TBL] [Abstract][Full Text] [Related]
29. The prognostic significance of CDKN2A homozygous deletion in IDH-mutant lower-grade glioma and glioblastoma: a systematic review of the contemporary literature.
Lu VM; O'Connor KP; Shah AH; Eichberg DG; Luther EM; Komotar RJ; Ivan ME
J Neurooncol; 2020 Jun; 148(2):221-229. PubMed ID: 32385699
[TBL] [Abstract][Full Text] [Related]
30. EFNA1 is a potential key gene that correlates with immune infiltration in low-grade glioma.
Hao YP; Wang WY; Qiao Q; Li G
Medicine (Baltimore); 2021 Jun; 100(22):e26188. PubMed ID: 34087884
[TBL] [Abstract][Full Text] [Related]
31. EPHA2 mediates PDGFA activity and functions together with PDGFRA as prognostic marker and therapeutic target in glioblastoma.
Gai QJ; Fu Z; He J; Mao M; Yao XX; Qin Y; Lan X; Zhang L; Miao JY; Wang YX; Zhu J; Yang FC; Lu HM; Yan ZX; Chen FL; Shi Y; Ping YF; Cui YH; Zhang X; Liu X; Yao XH; Lv SQ; Bian XW; Wang Y
Signal Transduct Target Ther; 2022 Feb; 7(1):33. PubMed ID: 35105853
[TBL] [Abstract][Full Text] [Related]
32. [Single-cell transcriptome analysis of multigrade glioma heterogeneity and immune microenvironment revealed potential prognostic biomarkers].
Liu J; Xu K; Ma L; Wang Y
Sheng Wu Gong Cheng Xue Bao; 2022 Oct; 38(10):3790-3808. PubMed ID: 36305410
[TBL] [Abstract][Full Text] [Related]
33. Identification of Critical m
Zheng J; Wang X; Qiu Y; Wang M; Yu H; Zhou Z; Wu Z; Jiang X
Biomed Res Int; 2021; 2021():9959212. PubMed ID: 34212046
[TBL] [Abstract][Full Text] [Related]
34. Low expression of insulin-like growth factor binding protein 7 associated with poor prognosis in human glioma.
Tian X; Zhang L; Sun L; Xue Y; Xie S
J Int Med Res; 2014 Jun; 42(3):651-8. PubMed ID: 24743871
[TBL] [Abstract][Full Text] [Related]
35. Recurrence- and Malignant Progression-Associated Biomarkers in Low-Grade Gliomas and Their Roles in Immunotherapy.
Teng C; Zhu Y; Li Y; Dai L; Pan Z; Wanggou S; Li X
Front Immunol; 2022; 13():899710. PubMed ID: 35677036
[TBL] [Abstract][Full Text] [Related]
36. CCNB2 is a novel prognostic factor and a potential therapeutic target in low-grade glioma.
Wang D; Sun H; Li X; Wang G; Yan G; Ren H; Hou B
Biosci Rep; 2022 Jan; 42(1):. PubMed ID: 34908101
[TBL] [Abstract][Full Text] [Related]
37. TERT promoter mutation status is necessary and sufficient to diagnose IDH-wildtype diffuse astrocytic glioma with molecular features of glioblastoma.
Fujimoto K; Arita H; Satomi K; Yamasaki K; Matsushita Y; Nakamura T; Miyakita Y; Umehara T; Kobayashi K; Tamura K; Tanaka S; Higuchi F; Okita Y; Kanemura Y; Fukai J; Sakamoto D; Uda T; Machida R; Kuchiba A; Maehara T; Nagane M; Nishikawa R; Suzuki H; Shibuya M; Komori T; Narita Y; Ichimura K
Acta Neuropathol; 2021 Aug; 142(2):323-338. PubMed ID: 34148105
[TBL] [Abstract][Full Text] [Related]
38. Exploring the Correlation of Abnormal CXCL9 Expression with Immune Infiltration in Glioma and Patient Prognosis Based on TCGA and GTEx Databases.
Liao Y; Liu B; Jin C; Liao X; Zhang Z
J Mol Neurosci; 2022 Dec; 72(12):2413-2424. PubMed ID: 36449138
[TBL] [Abstract][Full Text] [Related]
39. Correlation of immune phenotype with IDH mutation in diffuse glioma.
Berghoff AS; Kiesel B; Widhalm G; Wilhelm D; Rajky O; Kurscheid S; Kresl P; Wöhrer A; Marosi C; Hegi ME; Preusser M
Neuro Oncol; 2017 Oct; 19(11):1460-1468. PubMed ID: 28531337
[TBL] [Abstract][Full Text] [Related]
40. ECM2, a prognostic biomarker for lower grade glioma, serves as a potential novel target for immunotherapy.
Cheng X; Liu Z; Liang W; Zhu Q; Wang C; Wang H; Zhang J; Li P; Gao Y
Int J Biochem Cell Biol; 2023 May; 158():106409. PubMed ID: 36997057
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]